What is Altimmune's cash ratio?

Altimmune (ALT) reported cash ratio of 8.6× in Q1 2026.

How has Altimmune's cash ratio changed year-over-year?

Altimmune's cash ratio increased by 71.9% year-over-year, from 5× to 8.6×.

What is the long-term trend for Altimmune's cash ratio?

Over 5 years (2020 to 2025), Altimmune's cash ratio has grown at a -21.3% compound annual growth rate (CAGR), from 9.6× to 2.9×.

What does cash ratio mean?

Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.

Altimmune ALT Cash ratio

Cash ratio at other companies

Eli LillyLLY

0.1×0.0×

Merck & Co.MRK

0.2×-0.1×

Madrigal Pharmaceuticals, Inc.MDGL

0.7×-0.4×

Viking TherapeuticsVKTX

1.1×-0.8×

Wave Life SciencesWVE

10.9×+8.1×

Delcath SystemsDCTH

3.9×+1.4×

Other financials

Income statement

See full

Revenue$26.0K+420%

Operating income-$24.2M-11.1%

Net income-$22.6M-15.3%

EPS (diluted)-$0.18+30.8%

Balance sheet

See full

Cash & equivalents$97.6M+98.7%

Total debt$34.8M+14,092%

Total equity$284.0M+99.8%

Total assets$335.6M+113%

Cash flow

See full

Operating cash flow-$20.9M-24.4%

CapEx$21.0K—

Free cash flow-$21.0M—

Valuation

See full

Market cap$558.14M-2.1%

Enterprise value$495.27M-5.0%

P/S13,613.2×-24,380×

Profitability

See full

Operating margin-230,461%-82,087pp

Net margin-214,861%-76,057pp

FCF margin-17,806.8%-110,030pp

Returns & leverage

See full

Return on equity-42.7%-8.7pp

Debt / equity0.1×+0.1×

Current ratio29.6×+13.7×

Where this comes from

Calculated from Altimmune’s reported figures.

cash and equivalents/total current liabilities=8.6×

Based on the most recent quarter.

The official record: Altimmune’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Altimmune's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Altimmune's cash ratio?: Altimmune (ALT) reported cash ratio of 8.6× in Q1 2026.
How has Altimmune's cash ratio changed year-over-year?: Altimmune's cash ratio increased by 71.9% year-over-year, from 5× to 8.6×.
What is the long-term trend for Altimmune's cash ratio?: Over 5 years (2020 to 2025), Altimmune's cash ratio has grown at a -21.3% compound annual growth rate (CAGR), from 9.6× to 2.9×.
What does cash ratio mean?: Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.